# Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

> **NCT06931613** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed or Refractory Hodgkin Lymphoma
- Children
- Nivolumab
- Autologous Haemopoietic Stem Cell Transplant

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06931613
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06931613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06931613, "Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06931613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*